Written by bbc.com Published in Health
Docetaxel is normally given after hormone treatment has failed. But results, to be presented at the American Society of Clinical Oncology, will show earlier treatment can extend life expectancy from 43 to 65 months.
Experts said the findings from a trial in Britain and Switzerland were “potentially game-changing”. More than 40,000 men are diagnosed with prostate cancer and nearly 11,000 die in the UK each year.
During the trial, being run across Britain and Switzerland, 2,962 men took part in the trial and some were given six doses of docetaxol at the start of their treatment.
